Venous Malformations

Chapter
First Online:

Abstract

Venous malformation is a slow-flow vascular anomaly that results from abnormal morphogenesis of veins. This vascular malformation is typically sporadic; however, it may be inherited. It can present as a small, localized lesion or an extensive malformation involving multiple tissue planes and vital structures. This condition is problematic because it can expand and often recurs after treatment. Patients can experience bleeding, pain, thrombosis, and distortion/obstruction of anatomic structures. Treatment consists of sclerotherapy and/or resection. Venous malformations should be treated in a vascular anomalies center by a multidisciplinary team.

Keywords

Cutaneomucosal-venous malformation Glomuvenous malformation Sclerotherapy Venous malformation 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Gupta A, Kozakewich H. Histopathological of vascular anomalies. Clin Plast Surg. 2011;38(1):31–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Hassanein AH, Mulliken JB, Fishman SJ, et al. Venous malformation: risk of progression during childhood and adolescence. Ann Plast Surg. 2012;68(2):198–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Labauge P, Enjolras O, Bonerandi JJ, et al. An association between autosomal dominant cerebral cavernous and a distinctive hyperkeratotic cutaneous vascular malformations in 4 families. Ann Neurol. 1999;45:250–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Gen. 2009;41:118–24.CrossRefGoogle Scholar
  6. 6.
    Greene AK, Alomari AI. Management of venous malformation. Clin Plast Surg. 2011;38(1):83–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Notelet L, Houtteville JP, Khour S, et al. Proliferating cell nuclear antigen (PCNA) in cerebral cavernomas: an immunohistochemical study in 42 cases. Surg Neurol. 1997;47:364–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Sure U, Freman S, Bozinov O, et al. Biological activity of adult cavernous malformations: a study of 56 patients. J Neurosurg. 2005;102(2):342–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Bicer A, Gucu B, Ozkan A, et al. Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J Clin Neurosci. 2010;17:232–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Vikkula M, Boon LM, Carraway KL, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87:1181–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations (“glomangiomas”). Am J Hum Genet. 2002;70:866–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Brouillard P, Ghassibe M, Pennington A, et al. Four common glomulin mutations cause two thirds of glomuvenous malformations (“familial glomangiomas”): evidence for a founder effect. J Med Genet. 2005;42:e13.PubMedCrossRefGoogle Scholar
  13. 13.
    Labergele-Couteulx S, Jung HH, Labauge P, et al. Truncated mutations in CCM1, encoding KRIT1, cause cavernous angiomas. Nat Genet. 1999;23:189–93.CrossRefGoogle Scholar
  14. 14.
    Labauge P, Brunereau L, Levy C, et al. The natural history of familial cerebral cavernomas: a retrospective MRI study of 40 patients. Neuroradiology. 2000;42:327–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Pagenstecher A, Stahl S, Sure U, et al. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009;18:911–8.PubMedGoogle Scholar
  16. 16.
    Greene AK, Liu AS, Mulliken JB, et al. Vascular anomalies in 5621 patients: guidelines for referral. J Peditr Surg. 2011;46(9):1784–9.CrossRefGoogle Scholar
  17. 17.
    Johanisson E, Oberholzer M, Swahn ML, et al. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception. 1989;39:103–17.CrossRefGoogle Scholar
  18. 18.
    Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect. 2000;108(Suppl 5):785–90.PubMedGoogle Scholar
  19. 19.
    Heryanto B, Rogers PA. Regulation of endometrial endothelial cell proliferation by oestrogen and progesterone in the ovariectomized mouse. Reproduction. 2002;123:107–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Kayisli UA, Luk J, Guzeloglu-Kayisili O, et al. Regulation of angiogenic activity of human endometrial endothelial cells in culture by ovarian steroids. J Clin Endocrinol Metab. 2004;89:5794–802.PubMedCrossRefGoogle Scholar
  21. 21.
    Fishman SJ, Smithers CJ, Folkman J, et al. Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg. 2005;241:523–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Kubiena HF, Liang MG, Mulliken JB. Genuine diffuse phlebectasia of Bockenheimer: dissection of an eponym. Pediatr Derm. 2006;23:294–7.CrossRefGoogle Scholar
  23. 23.
    Mazoyer E, Enjolras O, Laurian C, et al. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol. 2002;24:243–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983;18:894–900.PubMedCrossRefGoogle Scholar
  26. 26.
    Adams DM, Wentzel MS. The role of the hematologist/oncologist in the care of patients with vascular anomalies. Pediatr Clin N Am. 2008;55:339–55.CrossRefGoogle Scholar
  27. 27.
    Paltiel H, Burrows PE, Kozakewich HP, et al. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology. 2000;214:747–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Choi DJ, Alomari AI, Chaudry G, et al. Neurointerventional management of low-flow vascular malformations of the head and neck. Neuroimag Clin N Am. 2009;19:199–218.CrossRefGoogle Scholar
  29. 29.
    Burrows RE, Laor T, Paltiel H, et al. Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin. 1998;16:455–88.PubMedCrossRefGoogle Scholar
  30. 30.
    Enjolras O, Ciabrini D, Mazoyer E, et al. Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. J Am Acad Dermatol. 1997;36:219–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144:873–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Berenguer B, Burrows PE, Zurakowski D, et al. Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg. 1999;104:1–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol. 2004;15:431–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg. 2008;47:4578–84.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Plastic and Oral SurgeryBoston Children’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of Plastic and Oral SurgeryBoston Children’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations